Merck KGaA
MRK: XETR (DEU)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€843.00 | Xcnlrqh | Htwlgfryw |
Merck KGaA's Prospects Remain Solid, Although COVID-19 Benefits May Not Last
Business Strategy and Outlook
Merck KGaA has made a series of acquisitions and divestitures in the past decade or so to position the group for solid long-term growth in three key segments: life sciences, performance materials, and healthcare. However, after robust results in 2020 and 2021 due to COVID-19-related benefits particularly in its life sciences business, we think the company's intermediate-term growth may soften toward more historic norms.